Stifel Nicolaus Begins Coverage on Puma Biotechnology (PBYI)
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an “outperform” rating on the stock.
Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 261.83 on Tuesday. Puma Biotechnology has a 52-week low of $33.70 and a 52-week high of $262.48. The stock has a 50-day moving average of $155.7 and a 200-day moving average of $106.3. The company’s market cap is $7.886 billion.
Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.39. Analysts expect that Puma Biotechnology will post $-3.81 EPS for the current fiscal year.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.